ECE2020 Audio ePoster Presentations Diabetes, Obesity, Metabolism and Nutrition (285 abstracts)
Combination of topiramate and empagliflozin is considered a good option for treatment of obesity
Mahmoud Younis
Egypt Ministry Of Health
,
Endocrinology
,
Kafr Elsheikh
&
Egypt
Objectives: The aim was to show if the combination of topiramate and empagliflozin have the greatest weight decreasing effect in comparison to each drug alone and to control.
Design: Observational cohort prospective study 6-month trial.
Materials and methods: Observational cohort prospective study with the following of 200 obese patients who were in 4 parallel groups. Had been monitored in a private clinic, each group 50 patient’s number, with 35 females and 15 males with 50 patients as a control.
The results show that both topiramate and empagliflozin have weight loss effect if used alone with significant P-value which is 0.0480 with topiramate and 0.0048 with empagliflozin and the greatest weight loss effect if used in combination with a P-value less than 0.0001.
Conclusion: Combination of topiramate and empagliflozin show a considerable reduction of body weight and so is considered as an option for treatment of obesity.
Keywords: obesity, empagliflozine, topiramate, combination therapy.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more